Ask the Doctor: Is there any increased risk of FL transforming during watch and wait?
Boyu Hu, MD (University of Utah Health), discusses the increased risk of transformation in follicular lymphoma and its impact on treatment effectiveness.
Lymphoma News
An Enduring Legacy of Hope and Impact
Chike Springer was many things — a husband, son, brother, uncle and patriot — but he was most known for his positivity and determination.
U.S. Food and Drug Administration Approves Loncastuximab Tesirine-lpyl for Large B-cell Lymphoma
Loncastuximab tesirine-lpyl is the first and only CD-19-directed antibody drug conjugate single agent approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Ask the Doctor: How can we determine the efficacy of the COVID-19 vaccine and how we may respond?
As the rollout of the new COVID-19 vaccines continues, there is constant new data related to the vaccines and their effects on individuals. While most of this data is preliminary, information related to the efficacy and effect of the vaccine…
Ask the Doctor: How do physicians determine when follicular lymphoma has transformed to DLBCL? What kind of tests or symptoms help doctors monitor this?
Transformed lymphoma occurs when an indolent lymphoma turns into a more aggressive one. A transformation occurs when genetic changes in the indolent lymphoma cells cause them to begin growing faster and behaving more aggressively. Lymphoma Research Foundation Grantee Raphael Eric…
Ask the Doctor: What is the current efficacy of oral therapies for marginal zone lymphoma?
There are several chemotherapy and targeted anticancer drugs approved or under investigation for the treatment of lymphoma. Unlike traditional chemotherapy that is administered intravenously (IV) in a hospital or clinic, oral therapies are administered via a pill, taken at home…
U.S. Food and Drug Administration Approves CAR T Cell Therapy for Follicular Lymphoma
Axicabtagene ciloeucel has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
Best Shot: A Story of Hope
When Chris Gorelik received news that his central nervous system lymphoma would leave him with months to live, he sought a second opinion and took a chance on a new treatment protocol — to give him a fighting chance to see his children grow up.
Addressing Cancer Survivorship
Emily Tonorezos, MD, MPH, Director of the Office of Cancer Survivorship at the National Cancer Institute (NCI), in the Division of Cancer Control & Population Sciences, shares what she and the agency are doing to raise awareness of and address issues that cancer survivors may face, as well as future directions in cancer survivorship research.
Patient Perspectives: Understanding Telemedicine
With telemedicine trending to be a mainstay in how healthcare professionals treat patients, Ameet Doshi, MD, MBA, Lead Hospitalist for Telemedicine at HealthPartners, shares what is contributing to the surge and how it affects lymphoma patients and survivors.